Trial Profile
Phase I Pharmacokinetic and Pharmacodynamic, Open-Label, Dose Escalation Study of Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Subjects With Metastatic Cancer Which Have Activated Akt Demonstrated by Immunohistochemistry.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Triciribine (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 30 Jun 2011 Actual end date (Sep 2010) added as reported by ClinicalTrials.gov.
- 30 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Feb 2010 Planned end date changed from Mar 2010 to Mar 2011 as reported by ClinicalTrials.gov.